id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2013-E-0263-0007,FDA,FDA-2013-E-0263,"Determination of Regulatory Review Period for Purposes of Patent
Extension; RECUVYRA; Affirmation",Notice,Determinations,2017-08-23T04:00:00Z,2017,8,2017-08-23T04:00:00Z,,2017-08-23T14:14:05Z,2017-17961,0,0,0900006482a9fe28
FDA-2013-E-0263-0006,FDA,FDA-2013-E-0263,Determination of Regulatory Review Period for Purposes of Patent Extension; RECUVYRA,Notice,Determinations,2017-08-21T04:00:00Z,2017,8,2017-08-21T04:00:00Z,2018-02-21T04:59:59Z,2017-08-21T15:53:20Z,2017-17566,0,0,0900006482a8d15e
FDA-2013-E-0263-0005,FDA,FDA-2013-E-0263,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2017-06-06T04:00:00Z,2017,6,2017-06-06T04:00:00Z,,2017-06-06T14:13:14Z,,0,0,090000648269719e